Trial · NCT07906197
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative Percent Recovery of Total Radiocarbon (14C) | From Day 1 to Day 10 | Percentage recovery of total radioactivity (14C) in urine, feces, and exhale was determined based on total administered dose. |
| Primary | Percentage of Metabolite Detected in Plasma ，Urine, Feces | From Day 1 to Day 10 | The percentage of major metabolites detected in plasma urine, feces following \[14C\]levornidazole disodium phosphate single dose administration |
| Primary | Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of levornidazole | From Day 1 to Day 10 | AUClast is defined as the concentration of drug from time zero to the last observable concentration. |
| Primary | Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of levornidazole | From Day 1 to Day 10 | AUCinf is defined as the concentration of drug extrapolated to infinite time. |
| Primary | Maximum Observed Plasma Concentration (Cmax) of levornidazole | From Day 1 to Day 10 | Cmax is defined as the maximum concentration of drug. |
| Secondary | Clearance (CL) of levornidazole | From Day 1 to Day 10 | CL is defined as the clearance following administration of the drug. |
| Secondary | The Volume of Distribution (Vd) of levornidazole | From Day 1 to Day 10 | Vd is defined as the volume of distribution of the drug. |
| Secondary | Time of Maximum Observed Plasma Concentration (Tmax) of levornidazole | From Day 1 to Day 10 | Tmax is defined as the time (observed time point) of Cmax. |
| Secondary | Apparent Terminal Elimination Half-life (t1/2) of levornidazole | From Day 1 to Day 10 | |
| Secondary | Mean Residence Time (MRT0-t) of levornidazole | From Day 1 to Day 10 | |
| Secondary | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Day 1 to Day 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07906197/registered